A critical problem in treating Clostridioides difficile infections is the possibility that the pathogen develops resistance to fidaxomicin, an antibiotic often prescribed as a first-line treatment. But current methods used to screen for fidaxomicin resistance are time-consuming and expensive, which could delay getting effective antibiotics to patients.